Clinical Trial Update: Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms [Phase 2]

View source ↗

Summary

Phase 2 study evaluating venetoclax in combination with azacitidine in advanced BCR-ABL negative myeloproliferative neoplasms is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloproliferative Neoplasm

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Myeloproliferative Neoplasm | Phase 2 | Status: RECRUITING